Rochester, NY, September 24, 2025 – After two decades of pioneering hematology and cancer stem cell research, Sanatela AT Medical Solutions Inc. proudly announces that the United States Patent and Trademark Office (USPTO) has officially issued its long-awaited patent for a revolutionary cancer detection and treatment platform.
This patent marks a transformative step in the fight against cancer by introducing The Sanatela Matrix a novel bioengineered extracellular matrix model derived from decellularized Wharton’s Jelly Matrix (DWJM). This technology replicates the natural environment where stem cells thrive, enabling scientists and oncologists to identify and study cancer stem cells in vitro (outside the body) with unprecedented accuracy.
Why This Matters
- Targeting the Root of Cancer: Unlike conventional approaches that often destroy only the bulk of a tumor, or the cancer cells, this breakthrough identifies the rare but aggressive cancer stem cells that are frequently resistant to chemotherapy. These stem cells are believed to be the main culprits behind cancer recurrence and metastasis for most cancers.
- Reducing Chemotherapy Deaths: Research suggests that isolating and testing treatments on these cells could help reduce up to 27% of deaths associated with chemotherapy, by allowing oncologists to better predict which drugs will work without subjecting patients to ineffective or overly toxic regimens.
- Precision-Guided Oncology: The Sanatela Matrix platform serves as a precision testing system, enabling oncologists to tailor therapies for individual patients by directly observing how their cancer stem cells respond to different treatments.
Expanding Cancer Applications
The issued patent covers a wide range of cancers, including but not limited to:
Leukemia, lymphoma, myeloma, breast cancer, prostate cancer, ovarian cancer, bladder cancer, lung cancer, brain cancer, melanoma, colorectal cancer, pancreatic cancer, liver cancer, and more.
This broad portfolio underscores the versatility and far-reaching potential of Sanatela’s patented technology.
A Two-Decade Journey
“This patent issuance represents the culmination of 20 years of relentless research, innovation, and hope,” said Professor Michael C. Crowley, JD, CEO and Co-founder of Sanatela AT Medical Solutions Inc. “This breakthrough is far more than a laboratory tool—it represents a critical step toward giving oncologists the ability to identify and target cancer stem cells with precision. By enabling truly personalized and potentially life-saving treatments, we believe this technology can change the standard of cancer care. We are now preparing to bring it to market as a Lab Developed Test, making this innovation accessible to patients and physicians in the near future.”
About Sanatela AT Medical Solutions Inc.
Sanatela AT Medical Solutions Inc. is a biotechnology company dedicated to advancing cancer research and treatment through cutting-edge stem cell science. With a focus on developing platforms that empower oncologists to deliver precision medicine, Sanatela is committed to reducing the global burden of cancer and improving patient outcomes. Sanatela is a majority owned subsidiary of The Crowley Center for Regenerative Biotherapeutics
Media Contact:
Professor Michael Crowley JD
Sanatela AT Medical Solutions Inc.
The Crowley Center for Regenerative Biotherapeutics LLC (AT Venture Center LLC)
(585) 755-1779 | info@atventurecenter.com | www.atventurecenter.com